Edition:
India

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

56.99USD
21 Aug 2019
Change (% chg)

$1.31 (+2.35%)
Prev Close
$55.68
Open
$56.47
Day's High
$57.19
Day's Low
$55.67
Volume
72,941
Avg. Vol
68,056
52-wk High
$58.90
52-wk Low
$29.08

Latest Key Developments (Source: Significant Developments)

Anika Therapeutics Entered Into An Accelerated Share Repurchase Agreement With Morgan Stanley & Co. Llc
Tuesday, 14 May 2019 

May 13 (Reuters) - Anika Therapeutics Inc ::ANIKA THERAPEUTICS INC - ENTERED INTO AN ACCELERATED SHARE REPURCHASE AGREEMENT WITH MORGAN STANLEY & CO. LLC.ANIKA THERAPEUTICS INC - PURSUANT TO A ASR AGREEMENT TO REPURCHASE $30 MILLION OF SHARES OF COMMON STOCK..ANIKA THERAPEUTICS INC - EXPECT ACCELERATED SHARE REPURCHASE PROGRAM TO BE COMPLETED BY Q1 OF 2020.  Full Article

Anika Therapeutics - Fourth Quarter Earnings Per Share $0.54
Friday, 22 Feb 2019 

Feb 21 (Reuters) - Anika Therapeutics Inc ::ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.54.Q4 REVENUE $27 MILLION VERSUS REFINITIV IBES ESTIMATE OF $26.2 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.33 -- REFINITIV IBES DATA.SEES FULL YEAR 2019 CAPITAL EXPENDITURES BETWEEN $5 MILLION AND $8 MILLION.SEES FULL YEAR 2019 TOTAL REVENUE TO BE APPROXIMATELY 3% TO 6% BELOW PRIOR YEAR LEVEL.  Full Article

Anika Reports Third Quarter 2018 Financial Results
Thursday, 25 Oct 2018 

Oct 24 (Reuters) - Anika Therapeutics Inc ::ANIKA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.53.Q3 REVENUE $26.8 MILLION VERSUS I/B/E/S VIEW $27 MILLION.Q3 EARNINGS PER SHARE VIEW $0.31 -- THOMSON REUTERS I/B/E/S.ANTICIPATES 2018 FULL YEAR PRODUCT REVENUE TO BE APPROXIMATELY 3% BELOW PRIOR YEAR.ANIKA THERAPEUTICS - CONTINUES TO EXPECT IT WILL RESUME SHIPMENT OF PRODUCTS THAT WERE SUBJECT OF PREVIOUSLY-DISCLOSED VOLUNTARY RECALL BY END OF YEAR.ANIKA THERAPEUTICS - TOTAL OPERATING EXPENSES ARE NOW EXPECTED TO BE REDUCED TO HIGH $80 MILLION RANGE FOR FULL YEAR OF 2018.  Full Article

Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Anika Therapeutics Inc ::ANIKA ANNOUNCES FDA 510(K) CLEARANCE FOR ITS INJECTABLE HA-BASED BONE REPAIR TREATMENT.ANIKA THERAPEUTICS INC - HA-BASED BONE VOID FILLER RECEIVED 510(K) CLEARANCE FROM U.S. FDA.  Full Article

Anika reports Q3 earnings per share $0.46
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika reports third quarter 2017 financial results.Q3 earnings per share $0.46.Q3 revenue rose 5 percent to $27.2 million.  Full Article

Anika completes enrollment in second pivotal phase III trial of cingal
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika Therapeutics - ‍Anika expects to complete cingal second pivotal phase III trial in first half of 2018 and anticipates FDA approval following year​.  Full Article

Anika Therapeutics announces regulatory approval for Monovisc® in Australia
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Anika Therapeutics Inc :Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints.Anika Therapeutics Inc - ‍Anika intends to further expand Monovisc into additional international markets in 2018​.  Full Article